drugset
drugset / Trial / NCT01087580

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

NCT01087580 ↗

Phase 2 Withdrawn Northwestern University Genzyme, a Sanofi Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone

Timeline

Start
2011-03
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Background Docetaxel Small molecule 75 mg/m2 Intravenous
Background Prednisone Other / unclassified 10 mg Oral

Indications

prostate cancer